62965-57-5

Basic information

• Product Name: ButanaMide, 2-aMino-3,3-diMethyl-, (2S)-
• Synonyms: ButanaMide, 2-aMino-3,3-diMethyl-, (2S)-;(S)-2-AMino-3,3-diMethylbutanaMide;L-tert-leucinamide
• CAS NO: 62965-57-5
• Molecular Formula: C₆H₁₄N₂O
• Molecular Weight: 130.18816
• EINECS: -0
• Mol File: 62965-57-5.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 242.7 °C at 760 mmHg
• Flash Point: 100.6 °C
• Appearance: /
• Density: 0.982 g/cm³
• Vapor Pressure: 0.0335mmHg at 25°C
• Refractive Index: 1.468
• Storage Temp.: 2-8°C(protect from light)
• PKA: 16.19±0.50(Predicted)
• CAS DataBase Reference: ButanaMide, 2-aMino-3,3-diMethyl-, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: ButanaMide, 2-aMino-3,3-diMethyl-, (2S)-(62965-57-5)
• EPA Substance Registry System: ButanaMide, 2-aMino-3,3-diMethyl-, (2S)-(62965-57-5)

Safety Data

• Hazardous Substances Data: 62965-57-5(Hazardous Substances Data)

Usage

General Description

Butanamide, 2-amino-3,3-dimethyl, (2S)-is a chemical compound that consists of a butanamide backbone with an amino and two methyl groups attached to the third carbon atom in a stereospecific arrangement. It is a chiral molecule with a specific spatial orientation of its atoms. ButanaMide, 2-aMino-3,3-diMethyl-, (2S)- is used in various chemical and pharmaceutical applications, including as a building block for the synthesis of pharmaceutical drugs and as a research tool in chemical and biochemical studies. Its chiral nature makes it a valuable tool for studying stereoselective reactions and asymmetric synthesis. Additionally, it has potential applications in the development of new drug molecules with specific biological activities.

InChI:InChI=1/C6H14N2O/c1-6(2,3)4(7)5(8)9/h4H,7H2,1-3H3,(H2,8,9)/t4-/m1/s1

Upstream product

• 77425-86-6 (±)-2-amino-3,3-dimethylbutanenitrile 
• 630-19-3 pivalaldehyde 
• 62965-56-4 L-tert-butylglycine-N-carboxyanhydride 
• 75158-11-1 2-<(S)-α-methylbenzylamino>-3,3,dimethylbutyramide 
• 340291-72-7 2-[1-(S)-aminocarbonyl-(2,2-dimethyl-propyl)-amino]-2-(R)-phenyl-acetamide 
• 372199-21-8 (S)-tert-butyl (1-amino-3,3-dimethyl-1-oxobutan-2-yl)carbamate 
• 340291-70-5 2-[1-(S)-cyano-(2,2-dimethyl-propyl)amino]-2-(R)-phenyl-acetamide 
• 75158-10-0 (S,S)-3,3-dimethyl-2-(1-phenylethylamino)butyronitrile 
• 62965-35-9 N-tert-butyloxycarbonyl-L-tert-leucine 
• 20859-02-3 L-tert-Leucine 
• 372199-34-3 Cbz-tBu-Gly-NH₂ 
• 1092540-46-9 (S)-2-((R)-2-amino-2-oxo-1-phenylethylamino)-3,3-d9-dimethylbutanamide 
• 62965-10-0 (S)-N-carbobenzoxy-tert-butylleucine 

Downstream Products

• 20859-02-3 L-tert-Leucine 
• 26782-71-8 D-tert-leucine 
• 62965-10-0 (S)-N-carbobenzoxy-tert-butylleucine 
• 139163-43-2 (S)-2-amino-3,3-dimethylbutanoic acid hydrochloride 
• 1185282-00-1 ADB-FUBINACA 
• 1185282-11-4 N-[(1S)-1-(aminocarbonyl)-2,2-dimethylpropyl]-1-benzyl-1H-pyrazolo[3,4-b]pyridine-3-carboxamide 
• 1012880-57-7 N-[(1S)-1-(aminocarbonyl)-2,2-dimethylpropyl]-3-(cyclohexylmethyl)-5-methyl-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 
• 910376-39-5 N-[(1S)-1-(aminocarbonyl)-2,2-dimethylpropyl]-2,3-dihydro-3-(3-hydroxy-3-methylbutyl)-2-oxo-1H-benzimidazole-1-carboxamide 
• 63038-26-6 (S)-2-amino-3,3-dimethyl-butyric acid methyl ester 

Relevant articles and documents

The Strecker reaction coupled to Viedma ripening: A simple route to highly hindered enantiomerically pure amino acids

The Strecker reaction is broadly used for the preparation of α-amino acids. However, control of enantioselectivity remains challenging. We here couple the Strecker reaction to Viedma ripening for the absolute asymmetric synthesis of highly sterically hindered α-amino acids. As proof-of-principle, the enantiomerically pure α-amino acids tert-leucine and α-(1-adamantyl)glycine were obtained.

INDAZOLE DERIVATIVES

This invention relates to compounds, pharmaceutical compositions and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a

BENZIMIDAZOLONE DERIVATIVES

This invention relates to compounds and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective am